Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 1
2010 1
2011 2
2012 1
2013 4
2014 1
2015 3
2016 2
2017 2
2018 3
2019 3
2020 14
2021 13
2022 9
2023 10
2024 6
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.
Yao H, Yan M, Tong Z, Wu X, Ryu MH, Park JJ, Kim JH, Zhong Y, Zhao Y, Voskoboynik M, Yin Y, Liu K, Kaubisch A, Liu C, Zhang J, Wang S, Im SA, Ganju V, Barve M, Li H, Ye C, Roy AC, Bai LY, Yen CJ, Gu S, Lin YC, Wu L, Bao L, Zhao K, Shen Y, Rong S, Zhu X, Song E. Yao H, et al. Among authors: zhong y. J Clin Oncol. 2024 Oct 10;42(29):3453-3465. doi: 10.1200/JCO.23.02044. Epub 2024 Jun 20. J Clin Oncol. 2024. PMID: 38900984 Clinical Trial.
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.
Yao H, Yan M, Tong Z, Wu X, Yin Y, Ryu MH, Park JJ, Jiang S, Kim JH, Wang S, Zhong Y, Voskoboynik M, Zhang J, Kaubisch A, Liu C, Chen Y, Im SA, Wu L, Liu Y, Ganju V, Barve M, Li H, Yao G, Yang M, Bao L, Zhao Y, Zhao J, Zhao K, Shen Y, Rong S, Zhu X, Song E. Yao H, et al. Among authors: zhong y. Signal Transduct Target Ther. 2026 Mar 19;11(1):104. doi: 10.1038/s41392-026-02612-9. Signal Transduct Target Ther. 2026. PMID: 41856971 Free PMC article. Clinical Trial.
Prospective cohort study to validate esophageal dose constraints and predictive models for esophagitis in patients with breast cancer undergoing hypofractionated regional nodal radiotherapy.
Wang DQ, Yan L, Wu HF, Zhong YH, Huang XB, Jin J, Zhong QZ, Zhao LN, Wang XH, Jing H, Tang Y, Song YW, Lu NN, Chen B, Liu YP, Qi SN, Tang Y, Zhai YR, Zhang WW, Li N, Li YX, Fang H, Hou XR, Zhang N, Wang SL. Wang DQ, et al. Radiother Oncol. 2025 Nov;212:111120. doi: 10.1016/j.radonc.2025.111120. Epub 2025 Sep 6. Radiother Oncol. 2025. PMID: 40921329
Longitudinal Analyses and Predictive Factors of Radiation-Induced Lymphopenia After Postmastectomy Hypofractionated Radiation Therapy for Breast Cancer: A Pooled Cohort Study of 2 Prospective Trials.
Zhao XR, Fang H, Jing H, Zhong QZ, Wu HF, Hou XR, Dong LH, Zhong YH, Jin J, Zhao LN, Wang XH, Yang WF, Tie J, Lu YF, Sun GY, Wang DQ, Tang Y, Qi SN, Song YW, Liu YP, Tang Y, Lu NN, Chen B, Zhang WW, Zhai YR, Hu SY, Zhang J, Li YX, Zhang N, Wang SL. Zhao XR, et al. Adv Radiat Oncol. 2025 Mar 12;10(5):101750. doi: 10.1016/j.adro.2025.101750. eCollection 2025 May. Adv Radiat Oncol. 2025. PMID: 40241739 Free PMC article.
79 results